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New tools are needed to enable rapid detection, identification, and reporting of infectious pathogens in 
a wide variety of point-of-care applications that impact human and animal health. In this work, we report 
the design, construction, and characterization of a platform for multiplexed analysis of disease-specific 
DNA sequences that utilizes a smartphone camera as the sensor in conjunction with a handheld 
instrument that interfaces the phone with a silicon-based microfluidic chip. Utilizing specific nucleic acid 
sequences for four equine respiratory pathogens as representative examples, we demonstrated the ability 
of the system to use a single droplet of test sample to perform selective qualitative determination of 
target sequences with integrated experimental controls in an hour. The system achieves detection limits 
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Infectious diseases, also known as communicable diseases, have emerged as a global challenge with 
increasing international transportation [1]. The speed, distance and quantity of outbreaks can be 
unprecedented [2]. Although the world’s leading causes of human mortality are shifting toward non-
communicable diseases overall, infectious diseases have been dominating contributors to deaths in the 
age group of 5-14 years [3]. In 2015, infectious diseases caused approximately 8.42 million deaths, 
accounting for 15% of the total global deaths, which is close to the number of deaths caused by cancers 
(around 8.76 million) during the same period [4]. Unfortunately, people in low-income settings are at 
greater risk for infectious diseases due to factors like inadequate drinking water, sanitation, hygiene and 
contaminated food [5, 6]. 
Besides causing enormous loss of human health and medical burden, infectious diseases also harm 
national economies when animals raised for human consumption or entertainment suffer from them [7]. 
Infectious diseases are significant contributors to morbidity and mortality in horses [8]. They cause the 
loss of valuable horses, cancellations of horse competitions, devastating the multi-billion-dollar horse 
industry. The largest recorded outbreak of equine herpesvirus-I (EHV-I) originated in the National Cutting 
Horse Association Western National Championship in 2011, involving more than 2000 horses in 19 U.S. 
states [9]. The battle against equine infectious diseases has never ended. In January 2017, more than 40 
outbreaks across the U.S. were reported [10]. Such outbreaks demonstrate the need for effective equine 
infection surveillance and control, in which early detection remains an important factor.  
Early-stage diagnosis not only facilitates effective medical treatment, but also delivers early warnings 
needed for containing local outbreaks, which decreases further negative impacts on the whole society 
[11]. Various detection methods have been developed for infectious diseases, including culturing 
infectious agents, serological tests of antibody response and nucleic acid tests [12]. The test time of these 
methods varies from a couple of hours to days. However, these methods generally require benchtop 
instruments handled by specialized staff in an established lab, which cannot be easily fulfilled in resource-
limited areas. Traditional methods also lack the capability to identify multiple pathogens in the same test 
generally. However, coinfections with more than one pathogen may be more severe than single-pathogen 




Emerging as a rapid, cost-effective and portable solution to infectious disease diagnosis, point-of-care 
(POC) devices take advantage of microfluidics and microfabrication techniques [14]. Some POC devices 
have been developed for performing nucleic acid testing (NAT) methods, such as polymerase chain 
reaction (PCR) [15] and loop-mediated Isothermal amplification (LAMP) [16], to obtain rapid, sensitive and 
specific responses. Nevertheless, there has been no POC device for multiplexed NAT of multiple equine 
infectious diseases so far. Integrating POC devices with smartphones could further reduce detection cost, 
because smartphones can be used to collect, process and transmit experimental data so that hardware 
design is less complex. The communicational nature of smartphones also promotes data sharing for a real-
time surveillance network. 
In this study, our objective is to develop a smartphone-based POC detection system for equine respiratory 
pathogens. Streptococcus Equi (S. Equi), Streptococcus Zooepidemicus (S. Zoo), Equine Herpesvirus-1 
(EHV-1), and Equine Herpesvirus-4 (EHV-4) were chosen as the pathogens of interest due to their 
widespread virulence among horse populations. Chapter 2 reviews the current diagnosis protocols of 
infectious diseases, basics of LAMP, and the state-of-the-art of POC diagnostic devices for NAT. Chapter 3 
describes the methods used in this work, including the design of the silicon microfluidic chip for LAMP, 
the automation of reagents deposition onto the chips, the experimental protocol of on-chip multiplexed 
detection and the other hardware devices for detection. After the LAMP reactions, a smartphone was 
used to take fluorescence images of the chips and obtain qualitative results. Chapter 4 then presents the 
experimental results for detecting four equine pathogens separately and a combination of two pathogens 
(EHV-1 and EHV-4). The limits of detection of our system were also characterized and compared with 





2. Literature Review 
2.1 Laboratory Diagnosis of Infectious Diseases 
A single pathogen can cause a wide variety of clinical symptoms, and the same symptom may result from 
many pathogens. For example, Zika virus infection can lead to non-specific symptoms including but not 
limited to rash, fever and vomiting, many of which overlap significantly with acute Dengue and 
Chikungunya virus infections [17]. Therefore, diagnostic methods for identifying specific pathogens are 
essential for clinical practice.  
Figure 2.1 shows a general scheme of laboratory diagnosis of infectious diseases. The type of laboratory 
test and specimen will be decided according to a patient’s symptoms. There are four main types of tests 
used for pathogen diagnosis: direct examination, culture, serology and genetic tests. The results of these 
tests help physicians make definitive diagnoses and select proper treatment for patients.  
Direct examination of infectious pathogens under a microscope is a straightforward method for diagnosis 
of infectious diseases. Most bacteria (0.2~10 um) and fungi (2~10 um) can be seen clearly with a light 
microscope, while viruses (20~400 nm) must be seen with an electron microscope, which is not easily 
accessible in resource-limited areas. Furthermore, various stains are needed to visualize and differentiate 
microorganisms in smears and histologic sections [18]. As a result, direct examination of pathogens may 
have limited POC applications.  
Culture remains the gold standard for identifying pathogens, but it is difficult or unavailable for some 
pathogens, for example, virus cultures in field laboratories [12]. Another drawback of culture is that it can 
take days or weeks to grow and identify pathogens, which is not desirable for acute infections like sepsis 
[19, 20]. Culture also greatly relies on laboratory facilities and specialized technicians so that it is not a 
preferable option for POC diagnosis either. Nevertheless, culture has its own advantage in terms of 
sensitivity, as the presence of a single live pathogen in the specimen can yield a positive result 
theoretically [18]. Besides, when we do not have a short list of all the potential candidates of the unknown 
pathogen, culture is indispensable as it can offer information for broad screening.  
Serological methods take advantage of the specific binding between antibodies and antigens, which are 
developed into immunoassays. Antigens can be used to detect circulating antibodies in blood or other 
body fluids as evidence of an infection [18]. Conversely, circulating antigens can also be detected by 
antibodies. The antigen-antibody binding is usually labeled with a radioisotope (radioimmunoassay, RIA) 
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or an enzyme (enzyme-linked immunosorbent assay, ELISA) for enhanced detection [21, 22]. As mature 
technologies, a wide spectrum of rapid immunoassays has been adopted for POC tests of pathogens with 
performance close to those of laboratory methods [23, 24]. The lateral-flow assays (LFAs) that provide 
visible results are most common commercially available POC screening tests for infectious diseases [25].  
 
 
Figure 2.1: Laboratory procedures used in a clinical diagnosis of infectious diseases [19]. 
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To detect pathogen-specific nucleic acid sequences, nucleic acid testing (NAT), mainly polymerase chain 
reaction (PCR), is almost exclusively performed in centralized laboratories with high-end instrumentation 
and skilled personnel due to its high complexity [26]. PCR is a three-step process (Figure 2.2) for amplifying 
a small amount of specific nucleic acid sequences in a test sample to achieve sufficient detection signal 
[27]. Different types of PCR have been developed, including real-time PCR for DNA detection, real-time 
reverse transcription PCR (RT-PCR) for RNA detection, quantitative PCR (qPCR) and digital PCR (dPCR) for 
quantitative measurement of targets [28, 29]. As the most well-developed molecular technique up to now 
with a wide range of clinical applications, PCR has been extensively studied for POC translations [15, 30-
33]. In these POC devices, miniatured thermocyclers are needed to provide reiterative temperature cycles 
in PCR, which complicates POC systems and limits detection speed.  
 
 
Figure 2.2: The standard PCR protocol. Step 1: raising the temperature of the reaction to 95 °C to separate the DNA strands; 
Step 2: lowering the temperature to 50~70 °C for the oligonucleotide primers to hybridize; Step 3: raising to the optimal DNA 
polymerase temperature 72 °C for primer extension. This process is repeated cyclically, creating many copies of the target 
sequence [33]. 
 
There are alternative amplification techniques that do not require thermocycling, known as isothermal 
amplification [34]. Table 2.1 compares PCR with some of these methods, including loop-mediated 
isothermal amplification (LAMP), strand displacement amplification (SDA) and rolling circle amplification 
(RCA). Each method has its own strengths and limitations, while their isothermal nature in common offers 
great potentials for POC applications [26].  
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Table 2.1: Comparison of Nucleic Acid Amplification Methods (reproduced from [34, 35]) 
Parameter PCR LAMP SDA RCA 
Temperature (°C) 94, 55~60, 72 60~65 37 37 
Sensitivity (copies) <10 <10 10 <10 
Linear  
Dynamic Range 
6~7 6 ND ND 
Primer Design Simple Complex Complex Simple 




- + - - 
Allow 
Quantification 
+ + ± - 
Commercial 
Availability 
+ - ± - 
Need 
Denaturation 
+ - + - 
Denaturing Agents Heat Betaine Restriction enzymes, 
Bumper primers 
Strand-displacement 
property of DNA 
polymerase 
(+: Demonstrated; -: Not available; ±: Limited applications; ND: No data) 
 
Introduced in 2000, LAMP employs a strand-displacing DNA polymerase and a set of four to six specially 
designed primers that recognize six to eight distinct sequences on the target pathogen DNA for isothermal 
amplification with high specificity, efficiency and rapidity [36, 37]. Figure 2.3 illustrates a typical LAMP 
process in detail. Reverse transcription LAMP (RT-LAMP) can be used to detect target virus RNA by simply 
adding a heat-stable reverse transcriptase to the LAMP reaction [38]. Due to the robustness of the DNA 
polymerase against contaminants, LAMP is suitable for field diagnosis and has already been used for the 
direct amplification of analytes from whole blood and saliva with minimal sample processing at the point-




Figure 2.3: Principle of loop-mediated isothermal amplification (LAMP) method. (a) Primer design of the LAMP reaction. For 
ease of explanation, six distinct regions are designated on the target DNA, labeled F3, F2, F1, B1c, B2c and B3 from the 5’ end. 
As c represents a complementary sequence, the F1c sequence is complementary to the F1 sequence. Two inner primers (FIP 
and BIP) and outer primers (F3 and B3) are used in the LAMP method. FIP (BIP) is a hybrid primer consisting of the F1c (B1c) 
sequence and the F2 (B2) sequence. (b) Starting structure producing step. DNA synthesis initiated from FIP proceeds as follows. 
The F2 region anneals to the F2c region on the target DNA and initiates the elongation. DNA amplification proceeds with BIP 
in a similar manner. The F3 primer anneals to the F3c region on the target DNA, and strand displacement DNA synthesis takes 
place. The DNA strand elongated from FIP is replaced and released. The released single strand forms a loop structure at its 5’ 
end (structure 4). DNA synthesis proceeds with the single-strand DNA as the template, and BIP and B3 primer, in the same 
manner as described earlier, to generate structure 5, which possesses the loop structure at both ends (dumbbell-like structure). 
(c) Cycling amplification step. Using structure 5 as the template, self-primed DNA synthesis is initiated from the 3′ end F1 
region, and the elongation starts from FIP annealing to the single strand of the F2c region in the loop structure. Passing through 
several steps, structure 7 is generated, which is complementary to structure 5, and structure 5 is produced from structure 8 in 
a reaction similar to that which led from structures 5–7. Specifically, intermediate structures 7a and 9a and structures 5a and 
10a (in the yellow boxes) are produced from structures 6 and 8, respectively. Structures 9a and 10a then form structures 9 and 
10, respectively, whereas the displaced strands 7a and 5a form the dumbbell-like structures 7 and 5, respectively. More 









Figure 2.4: Typical response time course for various laboratory tests. The entry points of detection vary for different tests. The 
earlier the time of detection and medical intervention, the more successful the prognosis will be for most infections [12]. 
 
In sum, while we focus on NAT and chose LAMP for our application, a wide spectrum of methods exists 
for the diagnosis of infectious diseases. The usefulness of any individual method differs for various targets, 
samples and test conditions. There is no single perfect solution, and a combination of methods may be 
the most appropriate. Figure 2.4 shows different entry points of some methods in the response time 
course of infections. As one of the methods capable of early-stage detection, NAT has the potential to 




2.2 Point-of-Care (POC) Nucleic Acid Testing (NAT) for Infectious Diseases 
Infectious disease-related NAT accounted for approximately two thirds of the global molecular diagnostics 
market in 2011, including disease diagnosis, viral load monitoring, pathogen typing, drug susceptibility 
testing and blood bank screening [42]. While centralized laboratories provide standard environment and 
personnel for NAT, a considerable amount of time and cost will be consumed by sample storage, 
transportation and laboratory logistics. Moreover, centralized laboratories may not be affordable, 
accessible or highly efficient in resource-limited areas. As a result, POC NAT has long been developed, 
aimed for good performance, fast turnaround time (TAT) and low cost. Challenges that need to be 
addressed in POC NAT include sample preparation, long-term storage of reaction reagents, ease of use 
and costs [43].  
Some commercially available NAT platforms that have the potential to be used at POC settings are listed 
in Table 2.2. While most NAT platforms are categorized as high complexity by the United States Clinical 
Laboratory Improvement Amendments (CLIA) and limited to central laboratories, the PCR-based 
GeneXpert system from Cepheid is the first NAT platform categorized as moderate complexity with fully 
automated sample-to-answer testing that can be used near patients in a hospital [26]. The sample 
preparation in this system is automated by employing embedded nucleic acid purification beads, a rotary 
valve for fluids control, and multiple cartridge chambers for holding reagents (Figure 2.5) [44]. The 
GeneXpert has been endorsed by the World Health Organization (WHO) to diagnose tuberculosis [45] and 
tested in primary-care settings in Africa [46], resulting in more patients starting same-day treatment.  
The FilmArray system from BioFire Diagnostics (Table 2.2) offers comprehensive nested multiplex PCR 
(nmPCR) for syndromic testing of respiratory, bloodstream and gastrointestinal infections, with up to 27 
targets in one test [47-49]. Each FilmArray pouch (Figure 2.6) contains reservoirs holding freeze-dried 
biomedical reagents, a blister for sample lysis with ceramic beads, a blister for nucleic acid purification 
with silica-magnetic beads, blisters for first-stage PCR and a 102-well array for second-stage PCR, in which 
the flow of liquid is regulated by electronically controlled valves that activate the pistons, bladders and 
hard seals in the system [47].  
NAT with simpler instrumentation is enabled by isothermal amplification methods that require minimal 
sample preparation, for example, Twirta and Genie III developed in the UK (Table 2.2). These systems 




Table 2.2: Representative Commercially Available POC NAT Platforms 








-Minimal dimensions (instrument only): 
4.0" x 12.0" x 11.7" (GX-I Unit) 
-Weight (instrument only): no data 
-Power requirements: AC 100-240 V, 
50-60 Hz 
-Fully integrated sample preparation for blood 
cultures, sputum sample, etc.  
-Single-use disposable polypropylene cartridge 
-More than 20 diagnostic tests available in menu 
-Multiplexity with up to 3 targets in a test  
-TAT from 18 to 150 min depending on tests, 








-Amplification: nested multiplex PCR 
-Minimal dimensions (instrument only): 
10" x 15.5" x 6.5" (FilmArray 2.0) 
-Weight (instrument only): 16 lbs 
-Power requirements: AC 100-240 V, 
50-60 Hz 
-Fully integrated sample preparation for blood 
cultures, nasal aspirates, etc. 
-Single-use disposable pouch 
-More than 80 targets available for testing 
-Multiplexity with up to 27 targets in a test 
-Pathogen identification by DNA melting analysis 
-TAT about 60 min  
-A CLIA-waived version (FilmArray EZ) available for 








polymerase amplification (RPA) 
-Dimensions (instrument only): 74 mm x 
178 mm x 188 mm 
-Weight (instrument only): 1 Kg 
-Power requirements: AC 100-240V, 47-
63 Hz 
-Manual sample preparation 
-Isothermal amplification at around 37-42˚C 
-TAT < 20 min (amplification results typically within 
3-10 min) 
-Test kits for research and development use only 
-A simplified version (Twirla) only incubates 
reactions and is used with standalone end-point 








-Dimensions (instrument only): 250 mm 
x 165 mm x 85 mm 
-Weight (instrument only): 1.75 Kg 
-Power requirements: DC 19 V or 
rechargeable Lithium Polymer (Li-Po) 
battery 
-Manual sample preparation (2 min) 
-No DNA extraction needed 
-Diagnostic testing available for more than 20 
targets  
-TAT <30 min  






Figure 2.5: Design of the GeneXpert instrument. (a) Photograph of the GeneXpert cartridge showing reagent reservoirs and 
the integrated PCR tube. (b) Illustration of the GeneXpert cartridge and nucleic acid purification valve body. (c) Detailed 
illustration of the GeneXpert cartridge valve body showing the location of the nucleic acid isolation matrix. For nucleic acid 
capture, a tissue lysate solution from one reagent chamber is flowed through the beads within the valve body. The bound 
nucleic acid is then washed, eluted, mixed with PCR reagents, and dispensed into the PCR tube. (Reproduced from [44].) 
 
 
Figure 2.6: A schematic of the pouch showing a trace of the blisters, channels, array wells and the functional areas of the pouch 
marked with red lines [47]. 
 
Microfluidic technologies that allow miniaturization and integration of complex functions have been 
studied and advertised for POC diagnostic applications for more than a decade [50, 51]. Figure 2.7 
summarizes the processing flows in traditional laboratory-based PCR and some of their translations in 
microfluidic PCR chips. Although these technologies were demonstrated for PCR, they can be translated 
for isothermal NAT as well. Among the currently available isothermal methods, LAMP is the most well 
characterized and widely studied for POC pathogen detection [16, 39, 52, 53]. There are many handheld 
portable devices that integrate only amplification and detection [54, 55], while simple manual protocol or 
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robust, cost-effective integrated module for processing a variety of complex biomedical samples remains 
a bottleneck for most POC NAT technologies [26, 56, 57]. 
 
 
Figure 2.7: Diagrammatic representation of the processing flows in PCR-based detection with the traditional techniques and 
translation into microfluidic technology [33]. 
 
The WHO has defined the term “ASSURED” to describe the ideal characteristics of diagnostic tests in 
resource-limited settings: affordable by those at risk of infection, sensitive (few false-negatives), specific 
(few false-positives), user-friendly (simple to perform and requiring minimal training), rapid (to enable 
treatment at first visit) and robust (no need for refrigerated storage), equipment-free and delivered to 
those who need it [58]. Few POC NAT technologies have met these requirements. For instance, eliminating 
equipment is rather difficult for POC NAT considering its complexity in sample preparation, amplification 
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and detection. In this aspect, some studies have demonstrated isothermal amplification without 
electricity, using chemical heat packs [59, 60] or even body heat [61]. One-step autonomous sample 
preparation for isothermal amplification (RPA) from whole blood was also achieved by employing a 
vacuum-powered microfluidic structure to separate blood cells and plasma (Figure 2.8) [59]. 
Most commercially available POC NAT systems still need alternating current (AC) power supply, 
connection to a laptop for software processing and other accessories for sample preparation. Therefore, 
they are more suitable for clinics than field diagnostics. Future technology development for POC NAT 
should be guided by a clear understanding of the target operation environment and clinical needs. As 
isothermal amplification methods offer greater potentials for minimal-instrumentation NAT than PCR, 
they are expected to be explore further for POC applications.  
 
Figure 2.8: The design enables simultaneous plasma separation and sample compartmentalization for digital isothermal 
amplification. (A) The photo of the sample preparation part on the device. (B) The schematic illustration of the microfluidic 
structure: blood cells drop below the microcliff gap because of sedimentation, and plasma near the top skims into the wells. 












3.1 Silicon Microfluidic Chip 
To perform multiplexed LAMP assays for up to eight pathogens, a silicon microfluidic chip was designed 
to have ten channels with a shared inlet (Figure 3.1). The dimensions of the chip are 25 mm × 15 mm × 
500 μm, the same as a standard SIM card. The dimensions of each channel’s detection region are 10 mm 
× 500 μm × 200 μm, corresponding to a volume of 1 μL. Two square markers below the channels are used 
for channel recognition in smartphone image analysis. The fabrication process has been described in detail 
[52] and shown in Figure 3.1(a).  
 
 
Figure 3.1: A silicon microfluidic chip for multiplexed LAMP detection. (a) Schematic diagram of the fabrication process for the 
chip. (b) Photo of a fabricated chip taken with a U.S. quarter. (c)  A scanning electron microscope (SEM) image of the cross-




3.2 Automated Deposition of LAMP Reagents 
An automatic printing process has been developed for injecting LAMP reagents into the microfluidic 
channels. A liquid handling system (Nano-Plotter, GeSIM Co.) is adopted to precisely dispense sub-
nanoliter (~0.25 nL) primer droplets through a piezoelectric pipette tip in non-contact mode. A microscope 
tube is mounted beside the piezoelectric pipette and connected to a camera to enable image recognition 
for target navigation (Figure 3.2).  
 
 
Figure 3.2: The microscope mounted beside the pipette station. A camera is on the top of the microscope tube for real-time 
imaging.  
 
To extract the coordinates of a target in microscope images, its magnification factor and the position of 
the microscope’s optical axis are needed. The magnification factor was calibrated by using an on-chip 
marker (Figure 3.3). The marker is a 0.5 mm × 0.5 mm square, and one pixel represents about 7.143 μm. 
Considering that the minimal moving step of the pipette is 10 μm, the magnification factor of about 58 is 
efficient for precise liquid handling. Figure 3.4 illustrates the offset between the microscope’s optical axis 
and the first pipette. To measure the offset, we first moved the microscope to make a target spot in the 
center of the microscope image, which means the optical axis is right above the target.  The pipette 
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location is recorded as its original location at that time. Then we moved the pipette to print on the target, 
which means that the pipette was right above the target. The relative distances from the pipette’s current 
location to its original location are the offset. 
 
Figure 3.3:  Scale measurement using the on-chip markers. 
 
 
Figure 3.4: The offset between the microscope’s optical axis and the first pipette. 
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Figure 3.5 shows the working flow of the process. First, chips are loaded on the printing plate in the Nano-
Plotter. The coordinates (x, y and z axis) of the top left corner of a chip’s upper surface will be input into 
the Nano-Plotter’s software system by using a contact sensor. If multiple chips are processed in the same 
experiment, the coordinates of the other chips will be calculated using those of the first chip. Then the 
microscope will be programmed to move over a chip, obtaining real-time video of the two markers at the 
bottom of the chip. The markers can be recognized by using the built-in functions in the software system, 
and the coordinates of their centers will be recorded (Figure 3.6). These coordinates can be used to locate 
channels on the chip, since the relative distances from the microfluidic channels to the markers are fixed. 
This recognition process will be performed for every chip on the printing plate. After gathering all the 
location information, a Python script will be used to generate XML code describing the printing spots and 
the number of liquid droplets at each spot, so that a pipette can be set to print LAMP reagents 
automatically.   
 
 
Figure 3.5: The working flow chart of the automated deposition system.  
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Figure 3.6: Recognition of two markers on a chip and report of their center coordinates. 
 
The automatic printing process is demonstrated in Figure 3.7. The pipette will be rinsed by deionized 
water for 30 seconds (Figure 3.7a) before taking liquid (positive control or primers) from a well plate 
(Figure 3.7b). A stroboscope program will then be used to check the quality of droplets (Figure 3.7c). 
Satellite droplets whose trajectories are more than 10 degrees away from the central axis of the pipette 
tip and instable droplets will cause failures in the program, which lead to restarting the current printing 
loop. Printing will be performed only after the droplet quality examination is passed (Figure 3.7d). The 
above steps will be repeated until all different reagents are printed. For each channel, in total 200 droplets 
are evenly printed at five spots that are 0.6 mm away from each other. Figure 3.7e shows channels with 
and without printed droplets. The droplets are uniform and evenly distributed as programed. Up to six 
chips in a row have been loaded onto the printing plate for primer deposition at the same time. The 
printing plate has sufficient room for about five rows of chips, indicating the potential of using Nano-





Figure 3.7: Automatic printing process. (a) The pipette is rinsed with DI water. (b) The pipette is programmed to move to a well 
plate and take liquid sample. (c) The stroboscope program used to check the quality of droplets. (d) Photo of printing droplets 




3.3 Protocol of On-Chip Multiplexed LAMP Reactions 
 
 
Four LAMP assays have been developed to demonstrate the ability of our system for multiplexed 
detection of pathogen-specific nucleic acid sequences. Streptococcus Equi (S. Equi), Streptococcus 
Zooepidemicus (S. Zoo), Equine Herpesvirus-1 (EHV-1), and Equine Herpesvirus-4 (EHV-4) were chosen as 
the pathogens of interest due to their prevalence among horse populations. The LAMP primers are listed 
Table 3.1: Sequences of the LAMP Primers 




[52] F3: AAA ACT AAG TGC CGG TGC2  
B3:  GAG GCG CCT TTT AGA AGA   
FIP: TAC GAC TAA CCT CAG AGT TCG CTA TCA GTA TTA GTT GCA ACA AGT 
G 
BIP: CGA CTC CAA GAT TAT CGC GTG ATT GAA CTT TTT GGG CTG ATG A 
Loop F: ACA GTT GTC CCT CCC AAC A  




[52] F3: AAA GAC CCT CAT GGG AAA T 
B3: CCT TAG TTG CCG CAT AGG 
FIP: CCT GAC TAA CCA AAT ATA AGC CCT TGA GCT GGA CGA TAA GAC CT 
BIP: TGT TGG ACG TAT TTT GGT TGC TCT TCT GAG CCT TCT AAA CCT G  





[62] F3: GGC ATT TAC GTG TGG TCC TT 
B3: TCG CGG GCA TTT TTG TAC C 
FIP: GTC CAG CAA CGG TGC GTT GTG GCA CGC TCG TTA ACA GT 
BIP: CGA GCC TGA AGG GGG AAA ACT GGA GCT GTG TGG AAA GTA GC 
Loop F: AGG TTG AGA CGG TAA CGC TG 





[62] F3: CAA GAC GTA ACA ACG GGA GT 
B3: CGC AAG TAA CGG CGA TGA 
FIP: CGC TCT CCG TTT TCT TCC GAC AAG CCA CCC AGG ATT AGT CAA 
BIP: TTA CCC GGA CGG CCT TCC AAC GGG CAT GTC CTC AAC AA 
Loop F: GCC TGC TAC TCC GCA TG 
Loop B: AGC GTT GTA TAT GAT GCA TCC CCT 
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in Table 3.1. The synthesized primers of each assay were rehydrated with TE buffer and then mixed and 
diluted for use. The mixture recipe of a set of LAMP primers for an assay is shown in Table 3.2. The recipe 
of a LAMP reaction mixture used for off-chip validation in a thermocycler is listed in Table 3.3. For on-chip 
tests, primers will be deposited on a chip prior use so that they will be replaced with nuclease-free water 
in an on-chip reaction mixture.  
 
Table 3.2: Mixture Recipe  
of a Set of LAMP Primers 
Primer Concentration 
F3 2.5 μM 
B3 2.5 μM 
FIP 20 μM 
BIP 20 μM 
LF 10 μM 
LB 10 μM 
 
Table 3.3: Mixture Recipe of a LAMP Reaction 
Ingredient Volume (μL) 
10mM dNTPs (New England Biolabs) 7 
10X Isothermal Amplification Buffer (New England Biolabs) 5 
5M Betaine (Sigma Aldrich) 4 
100mM Magnesium Sulfate Solution (New England Biolabs) 3 
Primer Mixture for an Assay 4 
8000units/mL Bst 2.0 Warmstart DNA Polymerase  
(New England Biolabs) 
4 
20X Evagreen Dye in Water (Biotium) 2.5 
Diethylpyrocarbonate(DEPC)-treated Nuclease-free Water 4.5 





To perform multiplexed detection of four pathogens, two channels are used as positive and negative 
control, respectively; the other eight channels are divided into four groups with two duplicates for the 
four assays. During the preparation phase of a chip (Figure 3.8), the primers and DNA of S.Zoo will be 
deposited in the positive control channel (the first channel in Figure 3.8a) on a cleaned chip, provided that 
the channel will always generate fluorescence signal under desirable experimental conditions. No 
reagents will be deposited in the negative control channel (the second channel in Figure 3.8a), so it is 
expected to remain dark after amplification. The negative control channel was used to provide the 
baseline of the output fluorescence signal. If there is no amplification in the positive channel or the 
negative control channel has amplification, the test is considered invalid. The primers of the four assays 
will be deposited in the corresponding channels as well (Figure 3.8b). An original primer mixture described 




Figure 3.8: Preparation of a chip. (a) Deposition of the positive control. (b) Deposition of primers in the eight channels which 
are divided into four groups with two duplicates for each assay. (c) The deposited reagents are drying on the chip. (d) The chip 
is covered by a layer of transparent double-side adhesive membrane with laser-machined holes that match the inlet and the 




After the deposited reagents are dried on the chip for storage (Figure 3.8c), the chip will be covered by a 
layer of transparent double-side adhesive (DSA) membrane (ARseal™ 90880, Adhesives Research) to seal 
the channels (Figure 3.8d). The DSA membrane forms a barrier to cross-contamination, and it is 
compatible with the reagents used in the amplification reaction. There are laser-machined holes on the 
membrane that match the inlet and the ends (outlets) of the channels for injecting reaction solution. At 
this stage, the chip is available for tests.  
In the phase of user operation, a 50-μL LAMP reaction mixture will be prepared as stated above and a 
single droplet (~15 μL) of the reaction mixture will be injected into the channels through the inlet (Figure 
3.9a). Then the chip will be sealed with a glass coverslip (GOLD SEAL® 63760-01, Electron Microscopy 
Sciences) by peeling off the top layer of the DSA membrane and binding it with the coverslip. The coverslip 
prevents evaporation through the holes in a LAMP reaction. The sealed chip will be heated at 65 ℃ for 
LAMP reactions (Figure 3.9b). Fluorescence will start to spread in channels after a while (Figure 3.9c) and 
can be detected by a smartphone for qualitative results after about 30 minutes (Figure 3.9d). 
 
 
Figure 3.9: (a) A LAMP reaction mixture injected into a chip. (b) A chip sealed with a glass coverslip and heated at 65 ℃. (c) 
Fluorescence output of the LAMP reactions emerges. (d) A chip after amplification with fluorescent positive control channel 
and two positive test channels. 
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3.4 The Chip Holder, Smartphone-based Reader and Heating Module 
3.4.1 The chip holder 
The chip is embedded within a plastic holder that is in the shape of a credit card (85.6 mm × 54.0 mm × 
0.8 mm). The holder is similar to a credit card except that the commonly seen security chip is replaced by 
the microfluidic chip. The card is designed to facilitate handling of the small microfluidic chip during the 
assay (to prevent the user from touching the chip, which may introduce contamination), and to provide a 
surface upon which barcoded information about the included assays can be printed, as shown in Figure 
3.10. For on-chip LAMP reactions and fluorescence detection, polyoxymethylene (POM) is selected as the 
card material due to its high thermal stability (-30 °C to 183 °C), low auto-fluorescence, low cost, ease of 
machining, and excellent dimensional stability. The chip is attached inside the card with adhesive, so the 
chip’s location within the imaging field of view is reproducible when the card is inserted into a reader. A 
quick response (QR) code will be used to hold information about the chip (Figure 3.10), such as its 
fabrication serial number, the assays within the ten channels and the date of primer deposition. 
 





3.4.2 The smartphone-based reader 
The smartphone-based reader measures the fluorescent emission from the on-chip LAMP reactions 
(Figure 3.11a). The system consists of a smartphone (Nexus 6; Motorola) and a 3D-printed plastic cradle. 
A schematic of the fluorescence imaging system is depicted in Figure 3.11b. The rear-facing camera is 
aligned a 525-nm long pass filter (#84-744; Edmund Optics) and a 12.5x macro lens (#TECHO-LENS-01; 
TECHO) in series. The long pass filter is selected according to the emission wavelength of the fluorescent 
dye (EvaGreen) used in the LAMP assay. We designed and built a customized light source module 
comprised of eight 485-nm blue LEDs (#XPEBBL; Cree Inc.) and four 490-nm short pass filters (#ZVS0510; 
Asashi Spectra) that cover each pair of LEDs to provide uniform excitation illumination that does not 
spectrally overlap with the dominant fluorescence emission wavelengths. The overall dimensions of the 
cradle are 90 mm × 70 mm × 95 mm, and the weight is approximately 15 ounces, excluding the phone. 
 
 
Figure 3.11: (a) Photo of the smartphone-based reader with the smartphone and a chip card. (b) The internal structure of the 
reader that integrates optical and electrical components used for smartphone fluorescence microscopy [52].  
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3.4.3 The heating module 
To provide a portable heating module for the on-site pathogen detection, an open-source thermocycler 
(OpenPCR, Chai Biotechnologies Inc.) is assembled and modified to heat on-chip LAMP reactions (Figure 
3.12). The original sample holding block on top of the thermal pad which was designed to hold standard 
PCR tubes has been replaced with a customized polyether ether ketone (PEEK) cradle to accommodate 
the chip holder (Figure 3.12b). When the chip holder is inserted into the cradle, the microfluidic chip fits 
well onto a copper plate where there is a temperature sensor embedded inside. By taking advantage of 
the Peltier effect, the same thermoelectric module (C2-25-1502, Tellurex Co.) is used for both the heating 
and cooling modes. The two modes can be switched by reversing the polarity of its applied voltage. The 
technical specifications are shown in Table 3.4. The heating module is adequate for both PCR and LAMP 
reactions. 
 
Figure 3.12: (a) The inner structure of the heating module. (b) The cradle with a heating plate which has an embedded 





Table 3.4: Technical Specifications of the Heating Module 
Parameter Value 
Average Heating/Cooling Rate 1 °C/s 
Working Temperature 10 ~ 105 °C 
Temperature Accuracy < ± 1 °C at 65 °C 
Dimensions  25 cm X 13 cm X 20 cm 
Weight 3.5 Kg 
Power 200 W 






4.1 Off-Chip Characterization of the LAMP Assays 
DNA samples of all the pathogens were extracted directly from the corresponding viral or bacterial stock 
by thermal lysis. Briefly, 1 mL of culture-grown equine pathogens are centrifuged at 12,000 rpm for 1 
minute. The supernatant is discarded and the remaining material is suspended in 200 uL of nuclease free 
water. The sample is next lysed at 95 ˚C for 5 minutes, followed by 3 minutes of centrifugation at 12,000 
rpm. The supernatant containing the extracted pathogenic DNAs is retrieved and ready for immediate use 
or stored at -80 ˚C until use.  
To determine the limits of detection (LODs) for the four LAMP assays and to validate the specificity of the 
primers to the target DNA sequences, the LAMP reactions were characterized in a standard benchtop 
thermocycler (Eppendorf Realplex Thermocycler). For the test at each concentration, the LAMP reaction 
mixture was allocated into three PCR tubes to replicate the detection with a volume of 8 μL in each tube. 
Plasmids were designed and fabricated that contain the target nucleic acid sequences, to assist in 
quantitation of detection limits.  The copy numbers of target DNA reported here represent estimates 
derived by using LAMP standard curves that were established using the synthetic plasmid targets of known 
concentrations (Figure 4.1), for which the threshold time for the plasmid concentration corresponds to 
the copy number of target nucleic acid derived from pathogen culture extract. As a comparison, the PCR 
assays of the four pathogens were also performed with plasmid templates (Figure 4.2). A linear fit 
between the log of the target DNA concentration and the threshold time was also observed.  
Figure 4.3 shows the baseline-subtracted amplification curves for the off-chip LAMP assay of S. Equi, S. 
Zoo, EHV-1, and EHV-4 using purified DNA templates, in which a series of target DNA concentrations 
spanning 3 to 6 log concentration range were tested one at a time. The lower LOD is determined to be 
5×104 copies/mL for S. Equi, 5×103 copies/mL for S. Zoo and EHV-1, and 1×103 copies/mL for EHV-4. Target 
DNA with a concentration below its LOD cannot be detected through the amplification reaction. A good 
linear fit was observed for the assays between the log of the target DNA concentration and the threshold 
time of the amplification (the time taken for an amplification curve to reach 20% of the maximum 
intensity), indicating good amplification efficiency of the LAMP assays.  
To demonstrate the specificity of our LAMP assays, which is critical to the multiplexed on-chip detection, 
each of the four target DNA sequences were tested against non-specific primer sets (Figure 4.4). Specific 
template-primer amplification is observed for all four assays.  
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Figure 4.1: Off-chip characterization of the four LAMP assays developed for the detection of equine respiratory infection 
pathogens using plasmid DNA templates. The amplification curves and the threshold time versus concentration relationships 





Figure 4.2: Off-chip PCR standard curves for the detection and quantification of equine respiratory infection pathogen DNA 
using plasmid DNA templates. The amplification curves and the threshold time versus concentration relationships are plotted 







Figure 4.3: Off-chip characterization of the four LAMP assays developed for the detection of equine respiratory infection 
pathogens using purified DNA templates. The amplification curves and the threshold time versus concentration relationships 







Figure 4.4: Off-chip verification of the LAMP assay specificity. The real-time reaction curves of (a) the S. Equi DNA, (b) S.Zoo 
DNA, (c) EHV-1 DNA and (d) EHV-4 DNA with all four primers and negative control. (Reprinted with permission from [52]. 





4.2 On-Chip Characterization of the LAMP Assays 
To validate the LAMP assays on the chips, a fluorescence microscope (Nikon Eclipse FN1) was used to 
capture real-time images of the on-chip LAMP reactions with a 2× objective and a Nikon 96311 B-2E/C 
FITC fluorescence filter. For fluorescence microscopy analysis of the LAMP reactions, a sealed chip with 
injected reaction mixture is placed on an INSTECT mK1000 heating stage located under the microscope’s 
objective. The field-of-view of the microscope is large enough to measure the fluorescence output from 
six channels on the chip at the same time. NIS Elements software provided by Nikon is programmed to 
capture fluorescence images at one-minute intervals with 9.6× gain and one-second exposure time. The 
fluorescence microscope was used to monitor the reactions within six channels for 60 minutes after the 
chip is heated at 65 °C.  
The series of images measured by the fluorescent microscope are saved as grayscale TIFF files. These 
images are imported into Matlab as a 1024 × 1280 matrix of 16-bit unsigned integers. The average pixel 
intensities in the regions of each channel are calculated and recorded. Since the image frames are taken 
at one-minute intervals, the average intensities of the six channels can be plotted as a function of time to 
generate amplification curves. 
Figure 4.5 shows the amplification curves from the on-chip characterization of the S. Zoo LAMP assay. We 
initially performed a negative control test (Figure 4.5a), where DI water was used as the test sample, and 
no S. Zoo DNA were included in the reaction reagents. As shown in Figure 4.5a, no amplification occurred 
without target DNA. Similarly, no amplification was observed with a DNA concentration at 5×103 
copies/mL for S.Zoo (Figure 4.5b). When the DNA concentration increased to 5×104 copies/mL, all six 
channels were observed to start amplification reactions within 60 minutes, and three of the six channels 
reached saturated fluorescent response by 30 minutes. Therefore, we estimated that the LOD for the on-
chip S. Zoo LAMP assay is 5×104 copies/mL. As the DNA concentration was further increased to 5×105 and 
5×106 copies/mL, all the channels provided uniform amplification within 20 minutes, as shown in Figures 
4.5(d-e). The identical protocol was performed to characterize the on-chip LOD for the S. Equi (Figure 4.6), 
EHV-1 (Figure 4.7) and EHV-4 assays (Figure 4.8), for which we obtained detection limits of 5×104 
copies/mL, 5×103 copies/mL and 5×103 copies/mL, respectively. This set of experiments shows that the 
on-chip LAMP assays, measured via the fluorescence microscope, provide similar detection limits as the 
same assays performed in the conventional off-chip format, using a commercially available instrument. 




Figure 4.5: On-chip characterization of the S. Zoo assay limit of detection. The negative control (a) and low-concentration test 
(b) show no amplification within 60 minutes. (c) The limit of detection for the on-chip reaction is 5×104 copies/mL. The 
amplification reactions begin within 15 minutes for the high-concentration tests at (d) 5×105 copies/mL and (e) 5×106 





Figure 4.6 On-chip characterization of the S. Equi assay limit of detection. (a) The low-concentration test at 5×103 copies/mL 
shows no amplification within 60 minutes. (b) The limit of detection for the on-chip reaction is estimated to be 5×104 
copies/mL. The amplification reactions reach plateau within 60 minutes for the high-concentration tests at (c) 5×105 copies/mL 






Figure 4.7: On-chip characterization of EHV-1 assay limit of detection. (a) The low-concentration test at 5×102 copies/mL shows 
no amplification within 60 minutes. (b) The limit of detection for the on-chip reaction is estimated to be 5×103 copies/mL. The 
amplification reactions generally reach plateau within 60 minutes for the high-concentration tests at (c) 5×104 copies/mL and 





Figure 4.8: On-chip characterization of EHV-4 assay limit of detection. (a) The low-concentration test at 5×102 copies/mL shows 
no amplification within 60 minutes. (b) The limit of detection for the on-chip reaction is estimated to be 5×103 copies/mL. The 
amplification reactions reach plateau within 60 minutes for the high-concentration tests at (c) 5×104 copies/mL and (d) 5×105 
copies/mL. (Reprinted with permission from [52]. Copyright (2017) American Chemical Society.) 
 
Table 4.1: Comparison of the Limits of Detection (LODs) of the Off-
chip PCR, Off-chip LAMP and On-chip LAMP Assays 






S. Equi 100 50 50 
S. Zoo 100 5 50 
EHV-1 100 5 5 
EHV-4 100 1 5 





4.3 Multiplexed Detection of Target DNA Sequences 
As described in Section 3.3, eight channels on a chip were used to detect four different target DNA 
sequences, with two replicate channels for each target. When pathogen-specific target DNA sequences 
are present in the sample injected into the microfluidic chip, their corresponding two channels as well as 
the positive control channel will generate an amplification reaction with associated fluorescent emission, 
while the other channels without specific targets should remain dark. By measuring the fluorescence 
output from each channel using the smartphone-based instrument and the software application, 
detection results can be quickly analyzed and displayed. 
Fluorescent images of chips were captured by the smartphone in JPEG format. Since the fluorescence 
emission from the chip is green light centered at 530 nm, only the green (G) channel intensity is used in 
the following image processing. Within each channel’s region of interest (40 × 700 pixels), the average 
and standard deviation (STD) of all the pixel intensities were calculated. The average intensity obtained 
from the negative control (Channel 2) indicated the background intensity. Due to a combination of factors 
including the fluorescence of unbound dye and the unfiltered reflected light, the intensity measured in 
the negative control lane is used as a baseline that is subtracted from the output intensity of all the other 
lanes. The threshold value was set to be half of the baseline-subtracted average intensity of the positive 
control, as the value that is used to differentiate a positive test (with target DNA) from a negative test 
(without target DNA). 
Figure 4.9 shows the results for the four experiments performed for the detection of each of the four 
pathogen-specific DNA sequences using our system at the endpoint of the assays. For the experiment 
shown in Figure 4.9a, the sample loaded into the chip contained S. Equi DNA at a concentration of 5×107 
copies/mL. As seen in the fluorescence image captured by the smartphone, Channels 3 and 4, where the 
S. Equi primers are deposited, became bright as the positive control (Channel 1). As shown in the bar 
graph in Figure 4.9a, only the intensities of lanes 3 and 4 are significantly higher than the threshold, while 
the intensities of all the other lanes are well below the threshold. The variation in the intensities of the 
negative channels for may due to background fluorescence from unbound EvaGreen dye molecules. The 
error bar in the figure represents the standard deviation of the pixel intensities within each channel. 
Similar experiments were performed with the target DNA sequences of the other three pathogens (Figure 
4.9b-d). The real-time measurement of the on-chip reactions when the sample contains only S. Zoo DNA 




Figure 4.9: Experiments demonstrating one-at-a-time detection of target DNA sequences. The smartphone-captured 
fluorescence images and average intensities from each channel are shown in (a) for S. Equi (5×107 copies/mL), (b) S. Zoo (5×106 
copies/mL), (c) EHV-1 (5×105 copies/mL) and (d) EHV-4 (2×106 copies/mL) detection. (Reprinted with permission from [52]. 
Copyright (2017) American Chemical Society.) 
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Figure 4.10: Real-time measurement of the on-chip reactions when the sample contains only S. Zoo DNA. The images were 
captured at one-minute intervals using the fluorescence microscope. The images captured at (a) 5 mins, (b) 10 mins, (c) 15 
mins, and (d) 20 mins are shown here. Only the positive control and channels deposited with S. Zoo primers became bright. 
(Reprinted with permission from [52]. Copyright (2017) American Chemical Society.) 
 
Due to the increased risks brought by co-infections and the fact that the same clinical symptom can be 
caused by infections from several agents, a POC test which can simultaneously detect multiple pathogen-
specific target sequences from a single specimen is highly desirable [15]. To further demonstrate our 
system’s ability to detect co-infections, two types of target DNA sequences, EHV-1 and EHV-4 DNA were 
introduced into the same test sample for on-chip detection. As shown in the fluorescence image in Figure 
4.11, the high-intensity channels can be clearly identified as Channel 1, the positive control; Channels 7 
and 8, which indicates the presence of EHV-1 DNA; as well as Channels 9 and 10, which indicates the 
presence of EHV-4 DNA. The channels corresponding to the positive targets are significantly brighter than 
the negative control and the channels without targets, and the threshold is able to differentiate between 





Figure 4.11: Demonstration of co-detection of two types of DNA sequences. The 16-μL DNA sample in the 50-μL reaction 
mixture contained 8 μL of EHV-1 DNA (5×105 copies/mL) and 8 μL of EHV-4 DNA (2×106 copies/mL). Channel 1 (the positive 
control), Channels 7 and 8 (the test channels for EHV-1), and lanes 9 and 10 (the test channels for EHV-4) became bright after 







5. Discussion and Conclusions 
The positive control is comprised of a set of primers and its matching template DNA to indicate that the 
microfluidic channels have been filled with fluid and that the thermal and sealing conditions required for 
the LAMP reactions have been provided to the chip.  While we have chosen to use the primer and target 
DNA for our S. Zoo assay, in principle any LAMP primer-target pair could be utilized, such as those for 
housekeeping genes. The negative control is without primers (no-primer control) in this work, while a 
negative control with primers but no target DNA (no-target control) might be a more rigorous option 
because sometimes non-specific amplifications will happen with only primers. The disadvantage of the 
no-target control is that each assay will need a separate negative control with its primers, which is not 
efficient in terms of cost or the space on a chip. The no-primer negative control provides the reference of 
the lowest background fluorescence, which acts as the fluorescence baseline in our image processing. 
We found that selecting the qualitative threshold as half of the difference between the positive and 
negative controls provided correct determinations of the presence of the target pathogen within a 
channel. This threshold acts like a median filter. Note that reactions with target DNA concentrations above 
the limits of detection yield approximately the same endpoint fluorescence intensity after a 30-minute 
LAMP reaction, thus the system is intended only to make determinations about the presence or absence 
of a pathogen, rather than to estimate its concentration. The threshold is experience-based and will be 
calibrated in the future if needed.  
An important application for the platform presented in this work is for mobile diagnostics of pathogen-
induced diseases. We envision our system to be compatible with existing DNA/RNA extraction kits that 
are commercially available for PCR without the need for additional laboratory capabilities.  We also 
envision using the system in the context of a mobile equine laboratory that would have a centrifuge and 
hotplate available for sample pre-processing.  Therefore, centrifugation and heat lysis were used to rapidly 
extract tested material from viral/bacterial culture media for the results reported here. Although it is 
possible to add integrated sample preparation into the microfluidic chip, these functions add complexity 
and cost to the system. Heat lysis was used for DNA extraction in our tests due to the simple protocol, 
short processing time (~10 minutes) and low cost. The total time to get test results from an original sample 
is within an hour typically.  
Fang et al. used microfluidic chips made of polydimethylsiloxane (PDMS) for LAMP reactions and a digital 
fiber optical sensor for quantitative readout based on turbidity in the reaction region [63, 64]. Although 
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the fiber optical system enables quantitative detection, its complexity increases the cost, and makes its 
operation more complex than desired in point-of-care situations. Moreover, PDMS tends to cause bubble 
formation or vapor evaporation that inhibits nucleic acid amplification, because it is porous and gas-
permeable [65]. To avoid this problem, simultaneous LAMP reactions in glass microcapillaries has been 
explored, but subtle manual operation is required for this system and only two targets were detected 
simultaneously in a test [66]. 
Compared to these approaches, our system has the following advantages. First, our silicon microfluidic 
chip can be fabricated using high-throughput technologies existing in semiconductor industry, and it is 
more mechanically and vapor-stable than PDMS chips for nucleic acid amplification. Second, our system 
facilitates simple user operation (Figure 3.9). The user can prepare clinical samples using standard 
methods according to the type and condition of specific samples, then inject prepared LAMP reaction 
mixture into a chip and seal it. After LAMP reaction, the user can simply insert the chip into our detection 
reader and take a photo of it using smartphone, then data processing will be done automatically in the 
smartphone. Last but not the least, our system offers a more compact solution to simultaneous detection 
of up to eight targets (with positive and negative controls) within an hour, with comparable sensitivity 
and specificity to lab-based standard methods. 
When the target DNA concentration in samples decreases, amplifications will happen later and more 
slowly than the reactions with high-concentration target DNA (Figure 4.10). The output fluorescence of a 
channel with low-concentration target DNA usually starts from some spots and then spread in the 
channel, and may not fill the whole channel. By analyzing the growth pattern of the output fluorescence, 
we may be able to further decrease our detection limits.  
As a conclusion, we demonstrated a rapid, multiplexed, and inexpensive system for smartphone-based 
detection and identification of pathogen-specific nucleic acid sequences within a single-droplet test 
sample. The system utilizes a microfluidic approach for performing isothermal amplification of a 
multiplexed array, and uses a smartphone to capture and analyze fluorescence images. The test results 
can be instantly shared to an online database for rapid reporting. To validate our system, four LAMP assays 
have been developed for four major pathogens (S. Equi, S. Zoo, EHV-1 and EHV-4) that cause equine 
respiratory infectious diseases. The detection sensitivity of our system is comparable to that of the 
corresponding PCR and LAMP assays performed on a conventional laboratory thermocycler. 
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By generating a positive/negative determination of the presence of specific pathogens with integrated 
experimental controls and replicates, this mobile system can assist physicians in rapid point-of-care 
decision-making for treatment and quarantine response that is currently not possible with tests 
performed at central laboratory facilities. We believe our system represents a significant stride toward a 
practical solution to infectious disease diagnostics in resource-limited settings. Since our system detects 
specific nucleic acid sequences, the applications of our system can span beyond infectious disease 







[1] A. J. Tatem, D. J. Rogers, and S. Hay, "Global transport networks and infectious disease spread," 
Advances in Parasitology, vol. 62, pp. 293-343, 2006. 
[2] C. Chang, K. Ortiz, A. Ansari, and M. E. Gershwin, "The Zika outbreak of the 21st century," Journal 
of Autoimmunity, vol. 68, pp. 1-13, 2016. 
[3] R. Lozano et al., "Global and regional mortality from 235 causes of death for 20 age groups in 1990 
and 2010: A systematic analysis for the Global Burden of Disease Study 2010," The Lancet, vol. 
380, no. 9859, pp. 2095-2128, 2012. 
[4] V. Feigin, "Global, regional, and national life expectancy, all-cause mortality, and cause-specific 
mortality for 249 causes of death, 1980-2015: A systematic analysis for the Global Burden of 
Disease Study 2015," The Lancet, vol. 388, no. 10053, pp. 1459-1544, 2016. 
[5] A. Prüss-Ustün et al., "Burden of disease from inadequate water, sanitation and hygiene in low- 
and middle-income settings: A retrospective analysis of data from 145 countries," Tropical 
Medicine & International Health, vol. 19, no. 8, pp. 894-905, 2014. 
[6] M. D. Kirk et al., "World Health Organization estimates of the global and regional disease burden 
of 22 foodborne bacterial, protozoal, and viral diseases, 2010: A data synthesis," PloS Medicine, 
vol. 12, no. 12, p. e1001921, 2015. 
[7] R. Alders, J. A. Awuni, B. Bagnol, P. Farrell, and N. de Haan, "Impact of avian influenza on village 
poultry production globally," Ecohealth, vol. 11, no. 1, pp. 63-72, 2014. 
[8] J. Weese, "Infection control and biosecurity in equine disease control," Equine Veterinary Journal, 
vol. 46, no. 6, pp. 654-660, 2014. 
[9] J. Traub-Dargatz et al., "Case - control study of a multistate equine herpesvirus 
myeloencephalopathy outbreak," Journal of Veterinary Internal Medicine, vol. 27, no. 2, pp. 339-
346, 2013. 
[10] Equine Disease Communication Center. (2017). Available: 
http://www.equinediseasecc.org/alerts/outbreaks 
[11] L. Steele, E. Orefuwa, and P. Dickmann, "Drivers of earlier infectious disease outbreak detection: 
A systematic literature review," International Journal of Infectious Diseases, vol. 53, pp. 15-20, 
2016. 
[12] S. M. Lemon, M. A. Hamburg, P. F. Sparling, E. R. Choffnes, and A. Mack, "Global infectious disease 
surveillance and detection: Assessing the challenges. Workshop summary," in Global Infectious 
Disease Surveillance and Detection: Assessing the Challenges. Workshop Summary, 2007: National 
Academies Press. 
[13] E. C. Griffiths, A. B. Pedersen, A. Fenton, and O. L. Petchey, "The nature and consequences of 
coinfection in humans," Journal of Infection, vol. 63, no. 3, pp. 200-206, 2011. 
[14] P. Yager, G. J. Domingo, and J. Gerdes, "Point-of-care diagnostics for global health," Annu. Rev. 
Biomed. Eng., vol. 10, pp. 107-144, 2008. 
[15] S. Park, Y. Zhang, S. Lin, T.-H. Wang, and S. Yang, "Advances in microfluidic PCR for point-of-care 
infectious disease diagnostics," Biotechnology Advances, vol. 29, no. 6, pp. 830-839, 2011. 
[16] P. Craw and W. Balachandran, "Isothermal nucleic acid amplification technologies for point-of-
care diagnostics: A critical review," Lab on a Chip, vol. 12, no. 14, pp. 2469-2486, 2012. 
[17] A. Ganguli et al., "Hands-free smartphone-based diagnostics for simultaneous detection of Zika, 
Chikungunya, and Dengue at point-of-care," Biomedical Microdevices, vol. 19, no. 4, p. 73, 2017. 
[18] K. J. Ryan and C. G. Ray, "Principles of laboratory diagnosis of infectious diseases," in Sherris 
Medical Microbiology, 5th ed. New York, NY: McGraw-Hill, 2010. 
[19] J. A. Washington, "Principles of diagnosis," in Medical Microbiology, S. Baron, Ed. 4th ed.: 
University of Texas Medical Branch at Galveston, 1996. 
47 
 
[20] N. Mancini, S. Carletti, N. Ghidoli, P. Cichero, R. Burioni, and M. Clementi, "The era of molecular 
and other non-culture-based methods in diagnosis of sepsis," Clinical Microbiology Reviews, vol. 
23, no. 1, pp. 235-251, 2010. 
[21] S.-M. Hsu, L. Raine, and H. Fanger, "A comparative study of the peroxidase-antiperoxidase method 
and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay 
antibodies," American Journal of Clinical Pathology, vol. 75, no. 5, pp. 734-738, 2016. 
[22] E. Engvall and P. Perlmann, "Enzyme-linked immunosorbent assay (ELISA) quantitative assay of 
immunoglobulin G," Immunochemistry, vol. 8, no. 9, pp. 871-874, 1971. 
[23] P. Von Lode, "Point-of-care immunotesting: Approaching the analytical performance of central 
laboratory methods," Clinical Biochemistry, vol. 38, no. 7, pp. 591-606, 2005. 
[24] T. Laksanasopin et al., "A smartphone dongle for diagnosis of infectious diseases at the point of 
care," Science Translational Medicine, vol. 7, no. 273, pp. 273re1-273re1, 2015. 
[25] V. Gubala, L. F. Harris, A. J. Ricco, M. X. Tan, and D. E. Williams, "Point of care diagnostics: Status 
and future," Analytical Chemistry, vol. 84, no. 2, pp. 487-515, 2012. 
[26] A. Niemz, T. M. Ferguson, and D. S. Boyle, "Point-of-care nucleic acid testing for infectious 
diseases," Trends in Biotechnology, vol. 29, no. 5, pp. 240-250, 2011. 
[27] R. K. Saiki et al., "Enzymatic amplification of b-globin genomic sequences and restriction site 
analysis for diagnosis of sickle cell anemia," Science, vol. 230, no. 4732, pp. 1350-1354, 1985. 
[28] C. A. Heid, J. Stevens, K. J. Livak, and P. M. Williams, "Real time quantitative PCR," Genome 
Research, vol. 6, no. 10, pp. 986-994, 1996. 
[29] B. Vogelstein and K. W. Kinzler, "Digital PCR," Proceedings of the National Academy of Sciences, 
vol. 96, no. 16, pp. 9236-9241, 1999. 
[30] C. S. Zhang and D. Xing, "Miniaturized PCR chips for nucleic acid amplification and analysis: Latest 
advances and future trends," Nucleic Acids Research, vol. 35, no. 13, pp. 4223-4237, 2007. 
[31] F. Ahmad and S. A. Hashsham, "Miniaturized nucleic acid amplification systems for rapid and 
point-of-care diagnostics: A review," Analytica Chimica Acta, vol. 733, pp. 1-15, 2012. 
[32] S. Yang and R. E. Rothman, "PCR-based diagnostics for infectious diseases: Uses, limitations, and 
future applications in acute-care settings," The Lancet Infectious Diseases, vol. 4, no. 6, pp. 337-
348, 2004. 
[33] C. Lui, N. Cady, and C. Batt, "Nucleic acid-based detection of bacterial pathogens using integrated 
microfluidic platform systems," Sensors, vol. 9, no. 5, p. 3713, 2009. 
[34] P. Gill and A. Ghaemi, "Nucleic acid isothermal amplification technologies—A review," 
Nucleosides, Nucleotides, and Nucleic Acids, vol. 27, no. 3, pp. 224-243, 2008. 
[35] M. Fakruddin et al., "Nucleic acid amplification: Alternative methods of polymerase chain 
reaction," Journal of Pharmacy And Bioallied Sciences, vol. 5, no. 4, pp. 245-252, 2013. 
[36] T. Notomi et al., "Loop-mediated isothermal amplification of DNA," Nucleic Acids Research, vol. 
28, no. 12, pp. e63-e63, 2000. 
[37] M. Parida, S. Sannarangaiah, P. K. Dash, P. Rao, and K. Morita, "Loop mediated isothermal 
amplification (LAMP): A new generation of innovative gene amplification technique; perspectives 
in clinical diagnosis of infectious diseases," Reviews in Medical Virology, vol. 18, no. 6, pp. 407-
421, 2008. 
[38] H. T. C. Thai et al., "Development and evaluation of a novel loop-mediated isothermal 
amplification method for rapid detection of severe acute respiratory syndrome coronavirus," 
Journal of Clinical Microbiology, vol. 42, no. 5, pp. 1956-1961, 2004. 
[39] A. Priye, S. W. Bird, Y. K. Light, C. S. Ball, O. A. Negrete, and R. J. Meagher, "A smartphone-based 
diagnostic platform for rapid detection of Zika, chikungunya, and dengue viruses," Scientific 
Reports, vol. 7, 2017. 
48 
 
[40] C. Toumazou et al., "Simultaneous DNA amplification and detection using a pH-sensing 
semiconductor system," Nature Methods, vol. 10, no. 7, pp. 641-646, 2013. 
[41] N. Tomita, Y. Mori, H. Kanda, and T. Notomi, "Loop-mediated isothermal amplification (LAMP) of 
gene sequences and simple visual detection of products," Nature Protocols, vol. 3, p. 877, 2008. 
[42] A. Niemz, T. M. Ferguson, and D. S. Boyle, "Point-of-care nucleic acid testing: User requirement, 
regulatory affairs and quality assurance," in Molecular Diagnostics—Current Research and 
Applications, J. F. Huggett and J. O'Grady, Eds. 1st ed.: Caister Academic Press, 2014. 
[43] V. Linder, "Microfluidics at the crossroad with point-of-care diagnostics," Analyst, vol. 132, no. 12, 
pp. 1186-1192, 2007. 
[44] S. Raja et al., "Technology for automated, rapid, and quantitative PCR or reverse transcription-
PCR clinical testing," Clinical Chemistry, vol. 51, no. 5, pp. 882-890, 2005. 
[45] (2010). WHO endorses new rapid tuberculosis test. Available: 
http://www.who.int/mediacentre/news/releases/2010/tb_test_20101208/en/ 
[46] G. Theron et al., "Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing 
for tuberculosis in primary-care settings in Africa: A multicentre, randomised, controlled trial," 
The Lancet, vol. 383, no. 9915, pp. 424-435, 2014. 
[47] M. A. Poritz et al., "FilmArray, an automated nested multiplex PCR system for multi-pathogen 
detection: Development and application to respiratory tract infection," PloS One, vol. 6, no. 10, p. 
e26047, 2011. 
[48] H. Salimnia et al., "Evaluation of the FilmArray blood culture identification panel: Results of a 
multicenter controlled trial," Journal of Clinical Microbiology, vol. 54, no. 3, pp. 687-698, 2016. 
[49] S. N. Buss et al., "Multicenter evaluation of the BioFire FilmArray gastrointestinal panel for 
etiologic diagnosis of infectious gastroenteritis," Journal of Clinical Microbiology, vol. 53, no. 3, 
pp. 915-925, 2015. 
[50] P. Yager et al., "Microfluidic diagnostic technologies for global public health," Nature, vol. 442, no. 
7101, pp. 412-418, 2006. 
[51] D. Mark, S. Haeberle, G. Roth, F. Von Stetten, and R. Zengerle, "Microfluidic lab-on-a-chip 
platforms: Requirements, characteristics and applications," in Microfluidics Based Microsystems: 
Springer, 2010, pp. 305-376. 
[52] W. Chen et al., "Mobile platform for multiplexed detection and differentiation of disease-specific 
nucleic acid sequences, using microfluidic loop-dediated isothermal amplification and 
smartphone detection," Analytical Chemistry, vol. 89, no. 21, pp. 11219-11226, 2017. 
[53] K. Hsieh, A. S. Patterson, B. S. Ferguson, K. W. Plaxco, and H. T. Soh, "Rapid, sensitive, and 
quantitative detection of pathogenic DNA at the point of care through microfluidic 
electrochemical quantitative loop-mediated isothermal amplification," Angewandte Chemie, vol. 
124, no. 20, pp. 4980-4984, 2012. 
[54] J. R. Choi et al., "An integrated paper-based sample-to-answer biosensor for nucleic acid testing 
at the point of care," Lab on a Chip, vol. 16, no. 3, pp. 611-621, 2016. 
[55] C. D. Ahrberg, B. R. Ilic, A. Manz, and P. Neužil, "Handheld real-time PCR device," Lab on a Chip, 
vol. 16, no. 3, pp. 586-592, 2016. 
[56] J. Kim, M. Johnson, P. Hill, and B. K. Gale, "Microfluidic sample preparation: Cell lysis and nucleic 
acid purification," Integrative Biology, vol. 1, no. 10, pp. 574-586, 2009. 
[57] M. A. Dineva, L. Mahilum-Tapay, and H. Lee, "Sample preparation: A challenge in the development 
of point-of-care nucleic acid-based assays for resource-limited settings," Analyst, vol. 132, no. 12, 
pp. 1193-1199, 2007. 
[58] D. Mabey, R. W. Peeling, A. Ustianowski, and M. D. Perkins, "Diagnostics for the developing 
world," Nature Reviews Microbiology, vol. 2, p. 231, 2004. 
49 
 
[59] E.-C. Yeh, C.-C. Fu, L. Hu, R. Thakur, J. Feng, and L. P. Lee, "Self-powered integrated microfluidic 
point-of-care low-cost enabling (SIMPLE) chip," Science Advances, vol. 3, no. 3, p. e1501645, 2017. 
[60] P. LaBarre et al., "A simple, inexpensive device for nucleic acid amplification without electricity—
toward instrument-free molecular diagnostics in low-resource settings," PloS One, vol. 6, no. 5, p. 
e19738, 2011. 
[61] Z. A. Crannell, B. Rohrman, and R. Richards-Kortum, "Equipment-free incubation of recombinase 
polymerase amplification reactions using body heat," PloS One, vol. 9, no. 11, p. e112146, 2014. 
[62] M. Nemoto, K. Tsujimura, T. Yamanaka, T. Kondo, and T. Matsumura, "Loop-mediated isothermal 
amplification assays for detection of equid herpesvirus 1 and 4 and differentiating a gene-deleted 
candidate vaccine strain from wild-type equid herpesvirus 1 strains," Journal of Veterinary 
Diagnostic Investigation, vol. 22, no. 1, pp. 30-36, 2010. 
[63] X. Fang, Y. Liu, J. Kong, and X. Jiang, "Loop-mediated isothermal amplification integrated on 
microfluidic chips for point-of-care quantitative detection of pathogens," Analytical Chemistry, 
vol. 82, no. 7, pp. 3002-3006, 2010. 
[64] X. Fang, H. Chen, S. Yu, X. Jiang, and J. Kong, "Predicting viruses accurately by a multiplex 
microfluidic loop-mediated isothermal amplification chip," Analytical Chemistry, vol. 83, no. 3, pp. 
690-695, 2011. 
[65] R. Liu, P. Grodzinski, J. Yang, and R. Lenigk, "Self-contained, fully integrated biochips for sample 
preparation, PCR amplification and DNA microarray analysis," in Integrated Biochips for DNA 
Analysis, R. Liu and A. Lee, Eds. New York, NY: Springer 2007, pp. 46-67. 
[66] Y. Zhang et al., "Point-of-care multiplexed assays of nucleic acids using microcapillary-based loop-
mediated isothermal amplification," Analytical Chemistry, vol. 86, no. 14, pp. 7057-7062, 2014. 
 
